Member access

4-Traders Homepage  >  Shares  >  Nyse MKT  >  CEL-SCI Corporation       US1508374097

Financials ($)
Sales 2015 0,38 M
EBIT 2015 -38,9 M
Net income 2015 -
Debt 2015 -
Yield 2015 -
Sales 2016 0,59 M
EBIT 2016 -38,8 M
Net income 2016 -35,9 M
Debt 2016 -
Yield 2016 -
PER 2015 -
PER 2016
Capi. / Sales 2015 251x
Capi. / Sales 2016 160x
Capitalization 95,2 M
More Financials
CEL-SCI Corp. is a biotechnology company, which is involved in the research and development of investigational immunotherapy products for the treatment of cancer and infectious diseases.The company's lead investigational therapy, Multikine, is being developed as a potential therapeutic agent... 
More about the company
03/18 CEL SCI : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year (form ..
03/12 CEL-SCI CORPORATION : Cel-Sci's Cancer Immunotherapy In Phase III Is Value Oppor..
03/09 CEL SCI : Secures Clearance to Conduct Phase III Trial in 21 Countries
03/06 CEL SCI : Updates on Patient Enrollment in 2015 for Its Phase III Head and Neck ..
03/04 CEL SCI : Exclusive Interview With CEL-SCI CEO Geert Kersten F..
03/04 CEL SCI : CEO Geert Kersten Interviewed by The Life Sciences Report
03/04 CEL SCI : Gets Clearance to Conduct Phase III Trial in 21 Countries
03/03 CEL SCI : NEW STORY CEL-SCI Reports 2nd Consecutive Month of Record Patient Enro..
More news
Sector news : Bio Therapeutic Drugs
09:14a Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stoc..
08:59a QUEST DIAGNOSTICS : Quintiles, Quest to test lab joint venture for drugmakers
06:25a Intercept Pharmaceuticals Announces Proposed Offering of Common Stock
More sector news : Bio Therapeutic Drugs
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes